Stocks to Watch 12-31-08

NORTHFIELD LABORATORIES INCORPORATED (NASDAQ: NFLD)
"Up 129.63% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/NFLD.php

Northfield Laboratories is a leader in developing a hemoglobin-based oxygen-carrying red blood cell substitute. The initial indication we are seeking for our investigational product PolyHeme is the treatment of life-threatening red blood cell loss when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme is a solution of chemically modified human hemoglobin that requires no cross-matching and is therefore compatible with all blood types. It has an extended shelf life in excess of 12 months.

NFLD News:

December 30 - BLA for PolyHeme® Accepted for Filing and Granted Priority Review

Northfield Laboratories Inc. (Nasdaq: NFLD) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for PolyHeme®, the Company’s investigative human hemoglobin-based red cell substitute for the treatment of life-threatening red blood cell loss when an oxygen-carrying fluid is required and red blood cells are not available. In addition, FDA has designated the submission for Priority Review, with a review goal date of April 30, 2009.

“Filing of our BLA for PolyHeme with Priority Review is a key milestone for Northfield,” said Steven A. Gould, M.D., Chairman and Chief Executive Officer. “We are now one step closer to delivering a potential life-saving therapy to patients who need transfusion in situations when blood is not available.”

Northfield announced that it had submitted the BLA for PolyHeme on October 29, 2008, based on its comprehensive development program, including data from its Multicenter Phase III randomized, double-blind trial involving 720 trauma patients. Findings from this study were presented at the American College of Surgeons, appeared online in the Journal of the American College of Surgeons in November, and are scheduled for publication in the print edition in January 2009.

EMAGEON INCORPORATED (NASDAQ: EMAG)
"Up 75.82% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/EMAG.php

Emageon provides information technology systems for hospitals, healthcare networks and imaging facilities. Its enterprise family of solutions includes RadSuite™, HeartSuite™ and other specialty suites. All Emageon solutions are built on a unified Enterprise Content Management system offering advanced visualization and infrastructure tools for the clinical analysis and management of digital medical images, reports and associated clinical content. Emageon's standards-based solutions are designed to help customers enhance patient care, automate workflow, lower costs, improve productivity and provide better service to physicians.

EMAG News:

December 29 - Health Systems Solutions and Emageon Extend Merger Closing

Health Systems Solutions, Inc. (OTCBB: HSSO) and Emageon Inc. (Nasdaq: EMAG) announced that they have agreed to extend the closing date for their pending merger to February 11, 2009.

"We are pleased that, with the cooperation of Emageon, we were able to come up with a timetable for the completion of the merger and we are confident that the combined enterprise will offer great opportunities for our shareholders, employees, and customers," said Stan Vashovsky, HSS' CEO and Chairman of the Board. "This extension will also allow us additional time to complete our integration plan for our technologies. As a result, we will be in a better position to immediately serve the market upon closing."

"Emageon is pleased that HSS and Stanford International Bank Limited have shown a commitment to complete our transaction and we look forward to completing the merger promptly for the benefit of our investors and maximizing the HSS/Emageon business opportunities for our customers and employees," said Chuck Jett, CEO of Emageon.

Each of the Parties will file with the Securities and Exchange Commission a Current Report on Form 8-K describing the amendments which were made to the transaction documents.

ABOUT HEALTH SYSTEMS SOLUTIONS

HSS is a technology and services company dedicated to bringing innovation to the health care industry. HSS' objective is to leverage current and next-generation technologies to offer value-added products and services which will generate improved clinical, operational and financial outcomes for our clients. The HSS portfolio of products and services extends across many segments of health care including home health care, medical staffing, acute and post-acute facilities, and telehealth/telemedicine, grouped into three segments: technology solutions, software and consulting.

WESTAFF INCORPORATED (NASDAQ: WSTF)
"Up 50.82% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/WSTF.php

Westaff provides staffing services and employment opportunities for businesses in global markets. Westaff annually employs more than 100,000 people and services thousands of client accounts throughout the United States.

WSTF News:

December 29 - Westaff Receives Proposal from Select Staffing

Westaff, Inc. (Nasdaq: WSTF), a leading provider of staffing services, announced that it has received a proposal from Koosharem Corporation (as Select Staffing) under which Select Staffing would acquire all of the outstanding shares of Westaff common stock not owned by DelStaff, LLC for $1.25 per share in cash and all of the shares owned by DelStaff, LLC (which shares represent approximately 49.3% of the outstanding shares of Westaff common stock) for first lien debt issued by Select Staffing having a value roughly equivalent to $1.25 per share.

Select Staffing’s proposal is subject to significant conditions, including the completion of due diligence and the satisfactory negotiation and execution of definitive transaction documents. There can be no assurance that Select Staffing’s proposal will result in a transaction. Westaff has agreed to an exclusive period of negotiation with Select Staffing through January 14, 2009 in order to consider and negotiate the proposed acquisition. Westaff continues to evaluate other alternatives including continuing its operations as an independent company.

TRIMERIS INCORPORATED (NASDAQ: TRMS)
"Up 47.83% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/TRMS.php

Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors.

TRMS News:

December 24 - Trimeris Receives NASDAQ Audit Committee Deficiency Notification

Trimeris, Inc. (Nasdaq: TRMS) communicated that on December 18, 2008, the Company had received a Nasdaq Staff Deficiency Letter stating that the Company was not in compliance with the Nasdaq audit committee requirement for continued listing as set forth in Marketplace Rule 4350 due to the resignation on December 15, 2008 of Director Kevin C. Tang. At the time of his resignation, Mr. Tang served on the Company's audit committee. His resignation was previously announced by the Company on a Form 8-K filed with the Securities and Exchange Commission on December 16, 2008.

Consistent with Marketplace Rule 4350(d)(4), Nasdaq will provide the Company with a cure period to regain compliance. The cure period runs until the earlier of December 15, 2009 or the Company's next annual meeting of stockholders. If the Company's annual meeting of stockholders is held before June 15, 2009, then compliance with the listing standard must be achieved no later than June 15, 2009.

BIOPURE CORPORATION (NASDAQ: BPUR)
"Up 74.48% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/BPUR.php

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure® [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the Company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the Company is developing Hemopure and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold more than 200,000 units of Oxyglobin since its launch.

BPUR News:

December 30 - Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance

Biopure Corporation (Nasdaq: BPUR) announced that it has received notice from The NASDAQ Stock Market stating that NASDAQ has again suspended enforcement of its minimum bid price and market value requirements for continued listing, thereby extending the Company's time in which to gain compliance. Enforcement of these rules is scheduled to resume on Monday, April 20, 2009.

The Company estimates, based on the information received, that it now has until June 15, 2009, to regain compliance with the $1.00 minimum bid price requirement. If, at any time before that date the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company should be provided written notification that it complies with the Marketplace Rule.

KIDSATIONAL INCORPORATED (OTC: KDSC)
"Up 46.67% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/KDSC.php

KidSational, Inc. engages in creating and distributing safety and educational programming for children. It offers child safety board games, educational toys, books, CD's, virtual games, feature film and television shows, clothing, other child safety products, and ancillary products, such as educational stickers and backpacks for families, schools, and institutions. The company markets its products through retail stores. KidSational was formerly known as Squaremoon, Inc. and ZDigital.com. The company was founded in 1998 and is based in Sanvannah, Georgia.

KDSC News:

December 22 - Kidsational Inc. Works Towards Regaining Shareholders' Confidence

Kidsational Inc.'s (OTC: KDSC) Chief Executive Officer Eric Stratton Racheff released the following statement:

“Since taking over as Chief Executive Officer this month, my first target has been to regain the confidence and belief of existing shareholders, then to instill that same confidence and belief into new and possible shareholders. It was decided that it was needed to be done on an immediate basis, so I decided in this effort to increase shareholder value I will be cancelling 25,000,000 of my personal shares to reduce the number of outstanding shares and add value to others.

“It is the company's intention to have the name change and ticker change executed in the middle of January of which the share cancellation will take place at the same time.

“Also in January our new board of directors will be taking shape with some very creative and assertive professionals.

“We wish everyone a Happy Holiday Season!”